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Influence of dialysis on plasma lipid peroxidation products and anti-
oxidant levels. In patients with end-stage renal failure (ESRF), the
incidence of atherosclerosis and cancer is increased. The importance of
lipid peroxidation (LPO) products in the pathogenesis of these complica-
tions has recently been emphasized. The LPO products nialondialdehyde
(MDA) and hexanal, lipophilic antioxidants and erythrocyte glutathione
(GSH) were estimated in 10 pediatric hemodialysis (HD) patients before
and after HD and in 11 peritoneal dialysis (CPD) patients. Before HD,
MDA was elevated [median (interquartile range): 384.5 (110 to 501) nM;
normal < 150 nMJ, whereas plasma hexanal levels were normal in all
patients [130.5 (88 to 222) nM; <320 nM]. HD decreased MDA concen-
trations on average by 88% but did not change hexanal levels. CPD
patients exhibited high plasma MDA concentrations [371 (287 to 468) nM],
whereas hexanal was in the low normal range [56 (51 to 80) nM].
Antioxidants were normal in both groups and unchanged during HD.
GSH decreased slightly during HD. We hypothesize that MDA may
accumulate in ESRF due to reduced plasma clearance. Our results argue
against a general increase of LPO in uremia.
Polyunsaturated fatty acids are oxidized in vivo by free radicals
and other reactive species. Subsequent degradation of oxidized
lipid molecules leads to the formation of several specific metab-
olites that include aldehydes of variable chain length [such as
malondialdehyde (MDA) and hexanal] [1].
These lipid peroxidation (LPO) products can structurally alter
DNA, RNA, body proteins and many other biomolecules [2]. The
mutagenicity of LPO products has been demonstrated in various
experimental models [3—5]. Oxidatively modified, but not native
low density, lipoprotein is recognized by scavenger receptors and
taken up by macrophages, inducing the development of foam cells
in vascular atheromas [6]. LPO products have been found in
atherosclerotic lesions [7].
In patients with end-stage renal failure, the incidence of cances
and atherosclerosis is increased [8, 9]. During hemodialysis (HD),
complement and leukocyte activation by contact with artificial
surfaces promotes the formation of free radicals [10]. Several
authors have found elevated levels of LPO products in HD
patients [1 1—14]. Based on these observations, oxidative stress has
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been inferred to occur during HD or in uremia leading to the
development of cancer and atherosclerosis in end-stage renal
failure. Malondialdehyde (MDA), a water-soluble LPO product,
is partially excreted via the urine under normal conditions [15—18].
However, it is not known which amount of MDA formed in the
body is eliminated by the kidney. It is therefore unknown whether
elevated MDA plasma concentrations in uremia reflects increased
LPO or reduced metabolic clearance. Although its metabolism is
even less known, the lipophilic LPO product hexanal [19] may be
a more adequate marker of LPO in patients with end-stage renal
failure, since renal clearance does not contribute significantly to
the metabolism of most lipophilic substances. Due to the absence
of blood contact with artificial surfaces, patients treated by
peritoneal dialysis are a particularly interesting population to
study the effect of uremia per se on LPO. Finally, the lipophilic
antioxidant spectrum has not been completely assessed in dialysis
patients [20—24]. In this study, we measured MDA, hexanal,
a-tocopherol, n-carotene, lycopene and cryptoxanthine in plasma
and erythrocyte glutathione content in pediatric patients with
end-stage renal failure on HD or continuous peritoneal dialysis
(CPD). In the HD patients. the effects of extracorporal blood
purification were assessed by repeated measurements immedi-
ately before and after the HD session.
Methods
Patients
Ten HD and 11 CPD patients attending our pediatric dialysis
unit were included in this study. The HD patients (5 m, 5 f) were
aged [median (interquartile range)] 15.4 (13.7 to 17.3) years and
their median duration of dialysis was 1.25 (0.6 to 2) years. The
CPD patients (8 rn, 3 f) were aged 15.5 (7.7 to 19.9) years and
their median duration of dialysis was 2.9 years (1.9 to 4.3).
The underlying renal disorders were hypo-/dysplastic kidneys
(N = 11), glomerulonephritis (3), nephronophthisis (2), cystinosis
(2), prune belly syndrome (1), shunt nephritis (1) or unknown (1).
All patients were treated with water soluble vitamins, erythro-
poietin and intravenous (HD) or oral (CPD) iron preparations.
HD patients received iron after withdrawal of blood samples at
the end of the HD session. Nineteen patients received vitamin D,
18 phosphate binders, 13 bicarbonate, 6 ACE inhibitors, 4 beta
blockers, 2 calcium antagonists, 4 diuretics, 3 were given growth
hormone.
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Table 1. Biochemical patient characteristics
Before HD After HD CPD
Age years
Duration of
15.4
(13.7-17.3) NS
1.25
15.5
(7.7—19.9) NS
2.9
dialysis years (0.6—2) (1.9—4.3)
Serum creatinine 9.6 1.25 7.1
mg/dI (8.6—12) (0.9—3.1) (6.6—11.3)
Serum urea 160 10.5 112
mg/dl (151—164) (8—34) (93—140)
Serum proteins 66.3 80.3 58.9
glliter (64.8— 68.8) (72.8—88.4) (52.7— 64.8)
Serum lipids 5.5 7.9 7.9
g/liter (4.9— 6.3) (5.8—9.4) (6.1—9.1)
Triglycerides 220 321 275
mg/dl (89—267) (93—489) (191—215)
Cholesterol 150 185 195
mg/dl (136—156) (170—211) (188—215)
Hemoglobin 10.0 10.9
gIdi (9.6—10.4) (9.3—11.6)
Standard 21.3 22.9
bicarbonate mw (18.7—23.1) (20.3—24.4)
Descriptive analysis, data are given as median (interquartile range).
Seven HD patients and 8 CPD patients had residual diuresis
between 50 and 1600 mi/day. Five patients received HD with
polysulfone filters and 5 patients used cuprophane filters. Stan-
dard bicarbonate buffer was used as dialysate. All HD patients
were dialyzed three times per week for four hours per session.
In the CPD patients, 1.0 to 4.25% glucose solutions were used,
with 4 to 10 exchanges of 750 to 1000 mI/rn2 dwell volumes,
resulting in a mean 24 hours total dialysate volume of 6.4 2.1
liter/rn2 body surface area (BSA).
Patients with acute infections or severe anemia (Hb < 8 g/dl)
were excluded from the study. Biochemical characteristics are
shown in Table 1. Informed consent was obtained from all
patients. The study was approved by the Ethical Committee of the
University of Heidelberg.
Assays
Blood was obtained from HD patients before and after four
hours of HD and from CPD patients between 9 and 11 a.m. during
regular outpatient visits. Blood samples were immediately mixed
with butylated hydroxytoluene (final concentration 5 xg/m1) to
prevent further oxidation and with K-EDTA (final concentration
1.6 mg/mi). Plasma was separated from erythrocytes by centrifu-
gation at 4°C and stored frozen at —70°C. One hundred microli-
ters of packed erythrocytes were precipitated in 150 d 5-sulfosal-
icylic acid (50 mg/mI), centrifuged and the supernatant stored
frozen at —20°C for subsequent measurement of intra-erythro-
cytic glutathione (GSH). Plasma MDA was determined after
sample preparation by the modified HPLC technique of Lepage et
al [25]. A
-Bondapack C 18 (10 ) column was used. The mobile
phase consisted of phosphate buffer (5 mM, pH 7), acetonitrile
and tetrahydrofurane (70:20:10). Normal range values for MDA
were derived from 14 healthy young adults and adolescents
measured in our laboratory. Plasma hexanal was measured using
a slightly modified HPLC method described by Holley et al [26].
During the derivatization step the samples were stabilized by
addition of 10 1.d of butylated hydroxytoluene (0.5%). Elution was
achieved by 30% acetonitrile in water for 10 minutes, then a linear
gradient to 65% acetonitrile in water for 15 minutes, and finally
30% acetonitrile in water for 10 minutes. Age-specific normal
range values for hexanal were calculated from 80 children [27].
Tocopherols and carotenoids were measured by HPLC according
to the method of Hess et al [28]. Age-specific normal range values
for tocopherol and carotenoids were calculated from 94 children
[29]. Erythrocyte glutathione was determined photometrically by
the DTNB [5,5'-dithio-bis(2-nitrobenzoic acid)] assay of Ander-
son [30]. Creatinine, urea, total plasma protein and plasma lipids
were estimated by automated procedures using a Cobas autoana-
lyzer.
Measurement of urinaiy MDA and hexanal excretion
Spot urine (collection time I hr) and plasma samples were
obtained from 6 healthy young adults (5 males, mean age 30 1.3
years) after stimulation of diuresis by an oral water load (1000
ml/1.73 m2 BSA), immediately stabilized with butylated hydroxy-
toluene as described above and frozen at —70°C. Plasma and
urinary MDA, hexanal and creatinine were determined as de-
scribed above, and the fractionate elimination rate was calculated
for MDA and hexanal [fractional elimination rate (substrate) =
(urinary substrate/plasma substrate) - (plasma creatinine/urinary
creatinine)].
Statistics
Nonparametric Wilcoxon statistics were used to assess the
significance of between-group differences (analysis of variance on
ranks; pre-HD vs. CPD) and within-group differences (Wilcoxon
signed rank test; pre-HD vs. post-HD). Significance was accepted
for P < 0.05 after applying the Bonferoni-HoIm correction for
multiple comparisons. The corrected P values are given in the
Results section and Tables.
Results
Plasma MDA concentrations in HD patients were elevated
prior to HD 13-fold compared to normal controls [median
(interquartile range) 385 (110 to 501) n, upper limit of control
values 150 nM]. The HD procedure resulted in a significant
decrease in plasma MDA levels [45 (16 to 228) n after HD, P =
0.0014; data are in Fig. 1A]. The change in MDA paralleled that
of creatinine in plasma [MDA/creatinine ratio 34.4 (10.4 to 56.6)
pre-HD vs. 26.5 (11.6 to 83.2) after HD, not significant]. The
post-HD plasma concentrations of MDA were still well above the
normal range in 3 of 10 patients. In the CPD group, plasma MDA
was elevated to a similar degree as in the HD patients pre-HD.
The fractional elimination rate of MDA in the 6 healthy young
adults studied here was 33 10%.
Plasma hexanal concentrations were normal in all HD patients
prior to HD [130.5 (88 to 222) nM, upper limit of normal range 320
nM; data shown in Fig. I B]. During HD, a slight increase in plasma
hexanal concentrations occurred [186 (122 to 262) nM after HD],
which was not significant when corrected for hemoconcentration
by calculating the hexanal/total protein ratio [1.91 (1.27 to 2.97)
nmol/g before HD vs. 2.4 (1.58 to 2.96) nmol/g after HD, not
significant]. In CPD patients, plasma hexanal concentrations were
in the low normal range, and significantly lower than in the HD
patients before and after HD [56 (51 to 80) nM, P = 0.045]. The
fractional elimination rate of hexanal was 2 0.2%. No differ-
ences in the changes in plasma MDA or hexanal levels were
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Fig. 1. Individual plasma Concentrations of
MD.4 (A) and hexanal (B) in HD patients before
and after HD session and in CPD patients.
Shaded area indicates the normal control range.
Table 2. Antioxidant status of patients
Before HD After HD CPD Normal
Glutathione 2.1 1.48 2.5 1.5—2.8
mM (1.8—2.3) (1.2—2) NS (2.1—3.3) NS
Cryptoxanthin 192 246 110 171
nM (146—313) (193—358)
P = 0.003
(71—154)NS (118—244)
Lycopene 717 881 738 509
flM (406—1116) (518—1367)
P = 0.032
(697—784) NS (322—710)
fl-Carotene 417 505 527 482
nM (281—773) (365—1088)
= 0.001
(291—704) NS (311—768)
a-Tocopherol 23.7 29.7 31.8 23.2
jiM (20.2—25.1) (24.8—33.4)
P 0.002
(22.5—40.2) NS (12.3—20.2)
Descriptive and comparative analysis, data are given as median (inter-
quartile range). Comparisons were made with values before HD, P values
show significant differences; NS. not significant. Normal values for Ii-
pophilic antioxidants are from [291.
observed between those patients treated with cuprophane and
polysulfone membranes, respectively.
The antioxidant status of the patients is shown in Table 2. The
lipophilic antioxidants were within the normal range in all patients
examined. No differences between the groups were observed. The
plasma concentrations of all lipophilic antioxidants increased
significantly during the HD procedure. However, when expressed
as antioxidant/lipid ratio, the levels remained stable during 1-ID
[antioxidants/lipid ratio in nmol antioxidant/g lipid before vs. after
FID, median (interquartile range): cryptoxanthine 34 (31 to 45) vs.
33 (25 to 54); lycopene 125 (73 to 188) vs. 121 (54 to 186);
[3-carotene 83 (61 to 127) vs. 80 (76 to 97); a-tocopherol 4330
(3966 to 4945) vs. 3970 (3715 to 4634), all NS].
The intra-erythrocytic concentrations of the hydrophilic antiox-
idant GSH decreased slightly during HD (NS). In the CPD
patients, normal intra-erythrocytic GSH concentrations were
found (Table 2).
Discussion
Recent methodological advances permit the measurement of an
increasing number of oxidation products in the body, which
exhibit different generation, distribution and elimination proper-
ties that are mostly unknown. To gain insight into their impor-
tance for pathological processes it is crucial to use specific
methods in determining their metabolic fate under different
normal and abnormal conditions.
Previously, LPO product formation has usually been measured
by determination of total thiobarbituric acid reactive substances
(TBARS). Elevated TBARS have been reported in patients with
chronic renal failure and on HD, and increased LPO has been
assumed to occur [12, 131. However, there are two pitfalls in this
conclusion. First, the TBARS assay is an unspecific overall
estimation of various substances, of which MDA is only one [31J.
Under pathological conditions such as uremia it might be even
more influenced by unknown accumulating or chemically modi-
fied substances. Second, whereas the production of aldehydes as
LPO products has been extensively studied [reviewed in 1], far less
attention has been paid to the further metabolic fate of these
compounds. MDA as a hydrophilic molecule formed upon oxida-
tion of w3- and wO-polyunsaturated fatty acids is partially excreted
with the urine under normal conditions [15—1 81. We quantified all
MDA-like substance in the urine of healthy adults. Its high
fractional clearance suggests a possible renal elimination pathway.
Thus, MDA accumulating in uremia may not necessarily result
from increased LPO. We were able to confirm by the use of a
specific HPLC method that MDA is in fact elevated in HI)
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patients [121. However, plasma MDA was elevated to a similar
degree in the patients on peritoneal dialysis. Moreover, plasma
MDA markedly decreased during the HD procedure, rendering
blood contact with artificial surfaces during HD as the major
source of MDA elevation unlikely. This is also confirmed by one
previous report of unchanged primary LPO products, measured as
lipid hydroperoxides, during HD [321. Thus, the increase in
plasma MDA concentrations appears to be a characteristic of
uremia per se rather than of HD treatment.
Hexanal is a specific oxidation product formed only from
w6-polyunsaturated fatty acids. Small quantities of hexanal are
always present in the plasma of healthy subjects, where it is
probably bound to proteins due to its hydrophobicity. Using a
specific HPLC method, we determined for the first time plasma
hexanal in dialysis patients. In contrast to MDA, plasma hexanal
concentrations were in the normal range. Hexanal increased
slightly during the HD procedure, but the hexanal/protein ratio
remained unchanged, suggesting low intradialytic clearance due
to high plasma protein binding. In CPD patients, plasma hexanal
levels were even lower than in HD patients. This observation is
likely due to peritoneal loss of the molecule comparable to the
changes observed with protein-bound metabolites, hormones and
drugs [33]. In contrast to MDA, the fractional elimination rate of
a hexanal-like substance in the urine of healthy young adults was
low, suggesting a predominantly nonrenal metabolism.
LPO is normally limited by a variety of biochemical defense
mechanisms. Tocopherols act as "chain breaking agents" through
a radical buffering function; they take up radical groups from
oxidized lipids, thus preventing the propagation of LPO [31.
Carotenoids are potent "radical quenchers" eliminating free
radicals from the aqueous phase [35]. In our patients, the levels of
all lipophilic antioxidants measured were within the normal range,
providing a sufficient buffering capacity to eliminate reactive
oxygen species before significant damage to body lipids would
occur. This finding is in good accordance with one previous report
of unchanged lag times of lipoprotein oxidation (a measure of the
antioxidative defense capacity of lipoproteins) during HD [36].
After binding to carotenoids or tocopherols, radical groups are
subsequently passed on by redox reactions to other antioxidative
systems, mainly ascorbate and glutathione [371. We observed a
slight, but not significant intradialytic decrease of GSH, which
may possibly result from the buffering of free radicals released
during the HD procedure or from dialytic removal of GSH
precursors. We did not measure the oxidized form of GSH,
GSSG. When increased proportions of GSSG are formed, it is
released from the intracellular space of the erythrocyte to the
plasma, where its concentrations are generally low and where it is
difficult to determine [38]. During HD, dialytic removal from the
circulation would most likely further limit the validity of this
parameter.
In summary, we observed a dissociated behavior of the two
LPO products MDA and hexanal in patients with end-stage renal
failure. This may result either from selectively increased degrada-
tion of only w3-polyunsaturated fatty acids or from compartmen-
tally different release of the two substances, with the compart-
ments generating MDA being more susceptible to oxidative
damage in uremia. Thirdly, the metabolic fate of hexanal and
MDA may differ, resulting in a selective accumulation of MDA in
uremia. The normal lipophilic antioxidant levels, suggesting a
sufficient capacity to prevent oxidative damage to polyunsaturated
fatty acids in uremia, lend further support for this possibility. Even
if elevated plasma levels of MDA do not result from enhanced
LPO in uremia, MDA may be regarded as a uremic toxin, since it
can form DNA adducts even under physiological conditions [391,
reacts with a wide variety of other biomolecules and produces
chroniosomal aberrations at the observed concentrations above
100 flM. Therefore, elevated MDA may well play a pathogenic role
in the increased incidence of cancer in patients with end-stage
renal failure.
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